Moderna director exercises 12,174 RSUs into shares

Moderna director Nader Francois increased his direct equity stake through RSU vesting, not open-market buying.

Rhea-AI Filing Summary

Moderna director Nader Francois increased his direct equity stake through RSU vesting, not open-market buying. On April 30, 2026, 12,174 restricted stock units converted into the same number of Moderna common shares on a one-for-one basis at an exercise price of $0.00 per share.

These RSUs vested in full on that date, reflecting compensation rather than a market trade. Following the conversion, Francois directly owns 32,781 shares of Moderna common stock.

Insider Trade Summary

12,174 shares exercised/converted

Exercise 2 txns

Insider Nader Francois

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	12,174	$0.00	$0.00
Exercise	Common Stock	12,174	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 0 contracts (Direct); Common Stock — 32,781 shares (Direct)

Footnotes (2)

1. F1. Restricted stock units convert into common stock on a one-for-one basis.
2. F2. The shares subject to this restricted stock unit award vested in full on April 30, 2026.

Key Figures

RSUs converted: 12,174 shares Exercise price: $0.00 per share Shares owned after: 32,781 shares +2 more

5 metrics

RSUs converted 12,174 shares Restricted stock units converted to common stock on April 30, 2026

Exercise price $0.00 per share Conversion of restricted stock units to common stock

Shares owned after 32,781 shares Total Moderna common stock directly owned after transaction

Transactions acquiring 2 entries Two acquire-side records related to RSU conversion

Derivative exercises 1 exercise, 12,174 shares Exercise or conversion of derivative security (RSUs)

Key Terms

Restricted Stock Units, derivative security, one-for-one basis, vested in full

4 terms

Restricted Stock Units financial

"The shares subject to this restricted stock unit award vested in full on April 30, 2026."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

derivative security financial

"transaction_code_description": "Exercise or conversion of derivative security""

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

one-for-one basis financial

"Restricted stock units convert into common stock on a one-for-one basis."

vested in full financial

"The shares subject to this restricted stock unit award vested in full on April 30, 2026."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Moderna (MRNA) director Nader Francois report in this Form 4?

Nader Francois reported the vesting and conversion of restricted stock units into Moderna common shares. On April 30, 2026, 12,174 RSUs converted one-for-one into 12,174 shares, increasing his direct ownership to 32,781 shares without any open-market purchase or sale.

How many Moderna (MRNA) shares did Nader Francois receive from RSU vesting?

He received 12,174 Moderna common shares through restricted stock unit vesting. The RSUs converted into common stock on a one-for-one basis at an exercise price of $0.00 per share, reflecting equity compensation rather than a cash transaction or open-market stock purchase.

What is Nader Francois’s Moderna (MRNA) shareholding after this transaction?

After the RSU conversion, Nader Francois directly holds 32,781 shares of Moderna common stock. This total includes the 12,174 shares issued upon full vesting of his restricted stock units on April 30, 2026, as disclosed in the Form 4 filing.

Was there any open-market buying or selling of Moderna (MRNA) shares in this Form 4?

No, the Form 4 shows no open-market buying or selling. It reports an exercise of derivative securities, where 12,174 restricted stock units vested and converted into 12,174 Moderna common shares as compensation, with an exercise price of $0.00 per share.

When did the restricted stock units for Nader Francois at Moderna (MRNA) fully vest?

The restricted stock units vested in full on April 30, 2026. On that same date, 12,174 RSUs converted into an equal number of Moderna common shares, as noted in the filing footnotes describing the vesting and one-for-one conversion terms.

How are Nader Francois’s restricted stock units in Moderna (MRNA) structured?

The restricted stock units convert into Moderna common stock on a one-for-one basis. In this event, 12,174 RSUs vested and were settled as 12,174 common shares at an exercise price of $0.00, illustrating a standard equity compensation arrangement for a company director.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/04/2026 - 04:48 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nader Francois

(Last) (First) (Middle)

C/O MODERNA, INC.

325 BINNEY STREET

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Moderna, Inc. [ MRNA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/30/2026		M(1)		12,174	A	(1)	32,781	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	04/30/2026		M(1)			12,174	(2)	(2)	Common Stock	12,174	$0	0	D

Explanation of Responses:

1. Restricted stock units convert into common stock on a one-for-one basis.

2. The shares subject to this restricted stock unit award vested in full on April 30, 2026.

	/s/ James Dillon, as Attorny-in-Fact	05/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)